Results

1–10 of 11 results for Treatment burden

12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Rishi P. Singh, MD
Annual Meeting Talks
2023
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023
Three-Year Outcomes of the PALADIN Phase IV Study: Comparison of Anatomical Metrics, Efficacy, and Treatment Burden Post FAc
Christopher D. Riemann, MD
Annual Meeting Talks
2022
The Role of Subretinal Surgery in the Treatment of Resistant Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Nabil M. Jabbour, MD, FACS
On Demand Cases, Courses, and Papers
2021
Episcleral Brachytherapy for Exudative Macular Degeneration
Gregg T. Kokame, MD, MMM, FASRS
On Demand Cases, Courses, and Papers
2020
Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Annual Meeting Talks
2020
High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis
Jared S. Nielsen, MD, MBA
Annual Meeting Talks
2020
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Annual Meeting Talks
2020
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020
Effect on Treatment Burden Post - Versus Pre-Iluvien Based on Prior DME Treatments
Caesar K. Luo, MD, FASRS
Annual Meeting Talks
2018